Overview

A Proof of Concept Pilot Study of the Addition of Venetoclax to Standard Remission Induction Chemotherapy Fludarabine, Cytarabine, and Granulocyte Colony Stimulating Factor (G-CSF) (FLAG) for Frontline Therapy of Secondary Acute Myeloid Leukemia

Status:
Not yet recruiting

Trial end date:
2025-03-01

Target enrollment:

Participant gender:

Summary

The primary purpose of this study is to determine complete remission rate of a novel combination induction chemotherapy treatment based upon 20 patients with newly diagnosed secondary AML.

Phase:

Phase 2

Details

Lead Sponsor:

University of Michigan Rogel Cancer Center

Treatments:

Venetoclax